De novo Inflammatory Bowel Disease following Liver and Heart Transplantation: A Case Series Exploring the Role of IL-23 Pathway-Targeted Therapy [0.03%]
肝移植和心脏移植后新发炎症性肠病：探索白细胞介素23途径靶向治疗作用的病例系列研究
Chihiro Shiomi,Ken Kurokawa,Sozaburo Ihara et al.
Chihiro Shiomi et al.
Introduction: De novo inflammatory bowel disease (IBD) is a rare but clinically significant complication after solid organ transplantation (SOT), with incidence higher than that in the general population. Its pathogenesis...
Efficacy and Safety of Ustekinumab in Asian Patients with Moderately to Severely Active Ulcerative Colitis: A Subpopulation Analysis of UNIFI Long-Term Extension through 4 Years [0.03%]
Ustekinumab治疗中重度活动性溃疡性结肠炎亚洲患者的有效性和安全性：UNIFI长期扩展研究（长达4年）的亚人群分析
Hyo Jong Kim,Satoshi Motoya,Yasuo Suzuki et al.
Hyo Jong Kim et al.
Introduction: This final long-term extension (LTE) analysis assessed long-term efficacy and safety of ustekinumab (UST) in the Asian patient subpopulation with ulcerative colitis (UC) in the UNIFI study. ...
Sisanda Nomcebo Mhlanga,Gordon Stanley Howarth,Suzanne Mashtoub
Sisanda Nomcebo Mhlanga
Background: Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic lifelong condition that affects the colon to a variable extent. Current treatments for IBD include aminosalic...
Real-World Adherence and Relapse Risk in Mesalamine Treatment for Ulcerative Colitis: Insights from a Large Japanese Medical Claims Database [0.03%]
基于日本大型医保数据库的美沙拉嗪治疗溃疡性结肠炎患者的真实世界依从性和复发风险分析
Takafumi Wada,Shuhei Hosomi,Yumie Kobayashi et al.
Takafumi Wada et al.
Introduction: 5-Aminosalicylic acid (5-ASA, mesalamine) is the cornerstone for maintaining remission in mild-to-moderate ulcerative colitis (UC), with several formulations available. Nonadherence to mesalamine is associat...
Safety and Effectiveness of Oral Budesonide after Endoscopic Balloon Dilation in Patients with Crohn's Disease: A Multicenter Prospective Intervention Study [0.03%]
内镜下球囊扩张后克罗恩病患者口服布地奈德的疗效及安全性：一项多中心前瞻性干预研究
Yuriko Otake-Kasamoto,Takeo Yoshihara,Shinichiro Shinzaki et al.
Yuriko Otake-Kasamoto et al.
Introduction: Budesonide, with its high topical steroidal activity, effectively prevents strictures following esophageal endoscopic treatment. However, its effectiveness in preventing restenosis after endoscopic balloon d...
Extraintestinal Manifestations and Cytomegalovirus Reactivation Are Predictors of Difficult-To-Treat in Ulcerative Colitis [0.03%]
溃疡性结肠炎伴发出血和巨细胞病毒再活化预示着难治性溃疡性结肠炎
Kotaro Akita,Mayuko Erata,Yoshihiro Yokoyama et al.
Kotaro Akita et al.
Introduction: Ulcerative colitis (UC) is a diffuse, nonspecific inflammatory disease of unknown etiology. Although corticosteroids are essential for inducing remission in moderate to severe UC, steroid dependence and refr...
Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis [0.03%]
优瑞克利姆与托法替布治疗溃疡性结肠炎的系统评价和网状Meta分析
Tareq Alsaleh,Abdul Mohammed,Aimen Farooq et al.
Tareq Alsaleh et al.
Introduction: Upadacitinib and tofacitinib, oral Janus kinase inhibitors, have demonstrated efficacy and safety in ulcerative colitis (UC) in clinical trials. However, real-world comparative data are limited. We conducted...
Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein Levels in Inflammatory Bowel Disease Patients across Racial Groups [0.03%]
评估炎症性肠病患者血清丰富α2糖蛋白水平的种族差异
Yasuhiro Aoki,Hiroki Kiyohara,Shinya Sugimoto et al.
Yasuhiro Aoki et al.
Introduction: Serum leucine-rich alpha-2 glycoprotein (LRG) has emerged as a novel biomarker for inflammatory bowel disease (IBD). However, its clinical utility among non-Japanese populations has not been investigated. Th...
Long-Term Outcomes and Prognostic Factors for Vedolizumab-Treated Japanese Patients with Ulcerative Colitis [0.03%]
维多珠单抗治疗溃疡性结肠炎患者的长期结局及预后因素
Shinya Fukushima,Takehiko Katsurada,Takahiro Ito et al.
Shinya Fukushima et al.
Introduction: Vedolizumab (VDZ) has been available for Japanese patients with ulcerative colitis (UC). However, real-world data regarding the long-term efficacy and safety of VDZ in Japanese patients with active UC remain...
A Retrospective Comparison of Postoperative Tumor Necrosis Factor-α Inhibitor Continuation versus Ustekinumab Switch in Crohn's Disease: Reset or Switch? [0.03%]
英夫利昔单抗维持治疗与乌司奴单抗转换治疗克罗恩病患者的术后对比研究：延续还是转变？
Shuhei Hosomi,Koji Fujimoto,Yumie Kobayashi et al.
Shuhei Hosomi et al.
Introduction: Ustekinumab (UST) is increasingly used in Crohn's disease patients with prior tumor necrosis factor-α inhibitor (TNFi) failure. However, whether to switch to another biologic or continue TNFi therapy at the...